Original Report

A qualitative exploration of supports and unmet needs of diverse young women with breast cancer


 

Background Young women with breast cancer face different challenges than those faced by older women because of their age and life stage, yet few studies have focused on the different challenges faced by women from diverse populations.
Objective To explore existing supports that are important during diagnosis and treatment and the unmet needs for information and support in young women with breast cancer.
Methods We conducted 20 semistructured interviews in English with women aged 42 or younger who had been diagnosed with stage I-III invasive breast cancer within the previous 4 years. We recorded and transcribed the interviews and used collaborative group immersion/ crystallization to analyze data, identify emergent themes, and determine if there were differences by race/ethnicity.
Results 20 participants, recruited from 9 US states and Canada, were interviewed, of whom 25% were Hispanic, 15% were black, 50% were white and non-Hispanic, and 10% were another race/ethnicity. Faith and/or spirituality and family were reported as important sources of support by many of the participants. Most of them lamented the inadequacy of their connections with other young survivors and also of supports for their family. Some recommended that young patients be provided with more information about: treatment-related physical and emotional changes; fertility and menopause; relationships after cancer; navigating work challenges; and transitioning into survivorship. None of these supports or recommendations was limited to a specific race/ethnicity or geographic region.
Limitations Small sample size, exclusion of non-English speakers. Conclusions Key informant interviews of young breast cancer survivors identified similar needs for education and support across various races/ethnicities and geographies.
Funding/sponsorship Supported by an ASCO Cancer Foundation/Susan G Komen for the Cure Improving Cancer Care Grant (PI: Partridge) and by NIH 5K05 CA124415-05 (PI: K Emmons).

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Genomic oncology: moving beyond the tip of the iceberg
MDedge Hematology and Oncology
Recurrence score assay driving chemo decisions in unexpected ways
MDedge Hematology and Oncology
Genetic biomarkers may be best bet for augmenting mammography screening
MDedge Hematology and Oncology
For metastatic breast cancer, adding pertuzumab not cost-effective
MDedge Hematology and Oncology
DCIS: Recurrence risk rises after forgoing radiotherapy
MDedge Hematology and Oncology
Fulvestrant may best anastrozole as first-line therapy
MDedge Hematology and Oncology
More genomic instability found in breast tumors of black women
MDedge Hematology and Oncology
LCIS: 2% annual cancer risk, less than 1% with chemoprevention
MDedge Hematology and Oncology
DCIS recurrences have declined significantly
MDedge Hematology and Oncology
Radiation + lumpectomy tied to increased survival in older women with TNBC
MDedge Hematology and Oncology